CureDuchenne has submitted comments to the U.S. Food and Drug Administration (FDA) on several proposed policies that could affect how new gene therapies and other genetic treatments are developed and reviewed for Duchenne muscular dystrophy, Becker muscular dystrophy, and other rare […]
As children with Duchenne muscular dystrophy grow, families often find themselves navigating new questions that extend beyond medical care. How can parents encourage independence while still providing support? What resources can help […]
Just a few years ago, families attending CureDuchenne’s FUTURES 2026 Annual Conference were weighing whether to participate in clinical trials. Today, the conversation has shifted dramatically. With multiple approved therapies now available for Duchenne muscular dystrophy (DMD), […]
When people think about physical therapy with Duchenne muscular dystrophy, they often picture stretching exercises or clinic visits. But at the CureDuchenne FUTURES 2026 Annual Conference, physical therapists Doug Levine, PT, and Jennifer Wallace, PT , […]
The neuromuscular disease community received encouraging news this week as Edgewise Therapeutics announced the sale of sevasemten and its Becker and Duchenne muscular dystrophy programs to Servier, a global pharmaceutical company with […]
CureDuchenne recently continued its commitment to improving global standards of care for Duchenne muscular dystrophy by participating in the first Latin American Duchenne Symposium in Santiago, Chile, followed by an […]
By Jason Mast
Emerging guidance offers cautious optimism—here’s what parents and caregivers should know For years, families affected by Duchenne muscular dystrophy have heard a consistent message: “be cautious with exercise, don’t overdo it.” That guidance came from a […]
